SCHEMBL3016983

SCHEMBL3016983

N#Cc1cc(Oc2c(Cl)ccc(CBr)c2F)cc(Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2C9 P11712 1/20 0.41
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR2A P28223 2/20 0.31
KCNH2 Q12809 2/20 0.31
LMNA P02545 1/20 0.30
ADRB2 P07550 1/20 0.30
MAPT P10636 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30
SLC6A4 P31645 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3034661 0.88 CYP3A4 (0.41) CYP3A4CYP2C19CYP2C9KDM4EMEN1
SCHEMBL3031434 0.81 CYP3A4 (0.40) CYP3A4CYP2C19CYP2C9KDM4EMEN1
SCHEMBL3022299 0.79 GRM5 (0.42) CYP3A4CYP2C19CYP2C9HTR2AKCNH2
SCHEMBL3635141 0.78 CYP3A4 (0.58) CYP3A4CYP2C19CYP2C9
SCHEMBL3022832 0.78 CYP3A4 (0.56) CYP3A4CYP2C19CYP2C9HTR2AKCNH2
SCHEMBL3638581 0.77 CYP3A4 (0.50) CYP3A4CYP2C19CYP2C9HTR2AKCNH2
SCHEMBL3034711 0.77 CYP3A4 (0.48) CYP3A4CYP2C19CYP2C9HTR2AKCNH2
SCHEMBL3017403 0.74 CYP3A4 (0.46) CYP3A4CYP2C19CYP2C9HTR2AKCNH2
SCHEMBL3023798 0.74 CYP3A4 (0.36) CYP3A4CYP2C19CYP2C9LMNAL3MBTL1
SCHEMBL3027986 0.74 CYP3A4 (0.35) CYP3A4CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304419-B2 Chemical compounds GLAXOSMITHKLINE LLC (US) 2012-11-06 US disclosed
US-20100216746-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-08-26 US disclosed
EP-2166856-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2010-03-31 EP disclosed
WO-2008154271-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216746-A1 CHEMICAL COMPOUNDS SAMHD1, POLRMT, NUDT1 CYP3A4 169/4885CYP2C19 842/4885CYP2C9 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.